Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 1;57(6):1018-24.
doi: 10.1002/pbc.23124. Epub 2011 Mar 28.

Sirolimus for the Treatment of Complicated Vascular Anomalies in Children


Sirolimus for the Treatment of Complicated Vascular Anomalies in Children

Adrienne M Hammill et al. Pediatr Blood Cancer. .


Background: Vascular anomalies comprise a diverse group of diagnoses. While infantile hemangiomas are common, the majority of these conditions are quite rare and have not been widely studied. Some of these lesions, though benign, can impair vital structures, be deforming, or even become life-threatening. Vascular tumors such as kaposiform hemangioendotheliomas (KHE) and complicated vascular malformations have proven particularly difficult to treat.

Procedure: Here we retrospectively evaluate a series of six patients with complicated, life-threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies.

Results: These patients showed significant improvement in clinical status with tolerable side effects.

Conclusions: Sirolimus appears to be effective and safe in patients with life-threatening vascular anomalies and represents an important tool in treating these diseases. These findings are currently being further evaluated in a Phase II safety and efficacy trial.

Comment in

  • Sirolimus for refractory vascular anomalies.
    Trenor CC 3rd. Trenor CC 3rd. Pediatr Blood Cancer. 2011 Dec 1;57(6):904-5. doi: 10.1002/pbc.23178. Epub 2011 Apr 29. Pediatr Blood Cancer. 2011. PMID: 21538825 No abstract available.

Similar articles

See all similar articles

Cited by 70 articles

See all "Cited by" articles